Skip to content
Trial Eligibility
Menu

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

NCT04047628

This study is recruiting at 19 US sites in 15 states, according to its ClinicalTrials.gov record last updated .

Summary

This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Relapsing Multiple Sclerosis
  • Relapsing Remitting Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis

Eligibility basics and study details

Study type
Interventional
Phase
Phase 3
Ages
18 to 55 years
Sex
All
Healthy volunteers
Not accepted
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Last updated on ClinicalTrials.gov
September 16, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

California · 1

  • Stanford Multiple Sclerosis Center · Palo Alto, CA

Colorado · 1

  • Rocky Mountain Multiple Sclerosis Center, University of Colorado School of Medicine · Aurora, CO

Illinois · 1

  • Northwestern University · Evanston, IL

Massachusetts · 1

  • University of Massachusetts Memorial Medical Center · Worcester, MA

Michigan · 1

  • Henry Ford Neuroscience Institute · Detroit, MI

Minnesota · 1

  • Mayo Clinic · Rochester, MN

Missouri · 1

  • John L. Trotter Multiple Sclerosis Center, Washington University School of Medicine in St. Louis · St Louis, MO

New York · 1

  • Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Siinai · New York, NY

Ohio · 2

  • University of Cincinnati (UC) Waddell Center for Multiple Sclerosis · Cincinnati, OH
  • Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic · Cleveland, OH

Oregon · 1

  • Multiple Sclerosis Center, Oregon Health & Science University · Portland, OR

Pennsylvania · 1

  • Penn Comprehensive MS Center, Hospital of the University of Pennsylvania · Philadelphia, PA

Texas · 2

  • University of Texas Southwestern Medical Center: Division of Multiple Sclerosis and Neuroimmunology · Dallas, TX
  • Maxine Mesigner Multiple Sclerosis Comprehensive Care Center, Baylor College of Medicine Medical Center · Houston, TX

Virginia · 2

  • University of Virginia · Charlottesville, VA
  • Virginia Commonwealth University Multiple Sclerosis Treatment and Research Center · Richmond, VA

Washington · 2

  • Multiple Sclerosis Center at Northwest Hospital · Seattle, WA
  • Multiple Sclerosis Center, Swedish Neuroscience Institute · Seattle, WA

Wisconsin · 1

  • Medical College of Wisconsin · Milwaukee, WI

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.